Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
ImmuCell Corporation is a specialty animal health company focused on bovine mastitis prevention and treatment products for dairy cattle. The company manufactures and markets First Defense (colostrum-based immune support for newborn calves) and is commercializing Mast Out (a non-antibiotic mastitis treatment targeting nisin-resistant bacteria). With a 30% gross margin and recent 52% revenue growth, ImmuCell operates in the niche veterinary biologics segment serving US dairy producers.
ImmuCell generates revenue by selling FDA-approved veterinary biologics directly to distributors and veterinarians serving dairy operations. First Defense commands premium pricing due to its unique antibody formulation and proven efficacy in reducing calf mortality. Mast Out represents a strategic shift toward recurring treatment revenue, targeting the $300M+ US mastitis treatment market with a differentiated non-antibiotic mechanism. The company benefits from regulatory barriers (USDA/FDA approval requirements) and established distribution relationships, though faces margin pressure from manufacturing scale limitations at current volumes.
Mast Out commercial adoption rates and quarterly sales trajectory in target dairy markets
First Defense volume trends correlated with US dairy herd size and calf birth rates
Manufacturing capacity expansion announcements and production efficiency improvements
Regulatory milestones including label expansions or additional product approvals
Dairy industry economics including milk prices and farm profitability affecting veterinary spending
US dairy herd consolidation reducing total farm count while increasing purchasing power concentration among large operators
Regulatory changes affecting veterinary biologics approval pathways or antibiotic alternative requirements
Long-term decline in US dairy consumption and potential herd size reduction impacting addressable market
Competitive development of alternative mastitis treatments or improved antibiotic formulations
Large animal health companies (Zoetis, Elanco, Boehringer Ingelheim) entering non-antibiotic mastitis treatment market with superior distribution
Generic or biosimilar competition to First Defense as patents age or regulatory exclusivity expires
Veterinary preference for established antibiotic protocols over novel nisin-based treatments requiring behavior change
Negative free cash flow (-$0.4M) requiring continued working capital management or potential equity raises for growth investments
Manufacturing capacity constraints limiting ability to meet demand spikes without capital expenditure
Small market cap ($100M) and limited trading liquidity creating volatility and acquisition vulnerability
moderate - Dairy farm economics are partially insulated from broader GDP cycles due to essential food production, but veterinary spending correlates with milk prices and farm profitability. During economic downturns, dairy producers may defer preventative treatments, though mastitis treatment remains critical. The 52% revenue growth suggests strong underlying demand despite macro headwinds. Dairy consolidation trends (larger, more professional operations) favor adoption of premium biologics.
Rising interest rates create modest headwinds through two channels: (1) higher financing costs for dairy farm capital expenditures reduce discretionary veterinary spending budgets, and (2) increased cost of capital compresses valuation multiples for unprofitable growth companies. However, ImmuCell's 4.21x current ratio and 0.46x debt/equity provide financial flexibility. The primary rate impact is valuation compression rather than operational stress.
Minimal direct credit exposure. ImmuCell sells through distributors with standard payment terms rather than extending significant credit to end customers. The company's strong current ratio (4.21x) indicates no near-term liquidity concerns. Indirect exposure exists if dairy farm credit conditions deteriorate, reducing veterinary product purchasing power, but this is secondary to milk price dynamics.
growth - The 52% revenue growth, 65% EPS growth, and 27% three-month return attract growth-oriented investors betting on Mast Out commercialization success. The micro-cap size ($100M market cap) and negative free cash flow appeal to speculative biotech investors rather than value or income investors. High volatility and binary outcomes around product adoption create momentum trading opportunities. Institutional ownership likely limited due to market cap constraints.
high - Micro-cap biotechnology stocks with single-product concentration and negative cash flow typically exhibit 40-60% annualized volatility. The 27% three-month move followed by flat six-month performance confirms episodic volatility around product milestones. Limited float and analyst coverage amplify price swings on news flow.